Answers are grounded in this paper and cite their sources.
DESIGN BLUEPRINT — SIMULATED, NOT MEASURED — NOT BUILT. Combined design blueprint for a single laboratory product family, the DNA cartridge line, derived from two source designs by the same author: 'DNA as a Data-Storage Chip' (DOI: 10.5281/zenodo.24108890) and 'DNA Strand-Displacement Computing for Molecular Diagnostics' (DOI: 10.5281/zenodo.24108813). Device A is a hybrid archival storage cartridge (25 x 25 x 1 mm, 10 mg dry DNA, 200 nt oligonucleotides: 20 nt primer + 20 nt address + 140 nt payload + 20 nt primer; 100 physical copies per distinct sequence; 35% error-correction overhead; 30x read coverage) with operational density 1.86 EB/g at operational redundancy, a mass-limited ceiling of 18.57 PB but a practical campaign fill of only 2.04 TB per cartridge (0.011% of the ceiling), writes in 12.1 h, reads in 14.5 h (4.0 h best selective case), zero retention energy, and a modelled array write cost of about $98,271 per GB (about $200,000,000 to write one campaign-filled cartridge; about $3,000,000 to read one in full). Device B is a single-use strand-displacement diagnostic cartridge evaluating YES = (miR-21 AND miR-196a) AND (CA19-9 OR KRAS G12D) in three logical layers in 50 uL of separated plasma at 37 C: net -6.9 kcal/mol per displacement, 76.8 s per gate, 12.8 minutes worst-case evaluation, usable depth limit about 6 layers, maximum fan-out 10, signal-to-leak ratio 17.3 at depth 3, decision threshold 30% of full reporter signal, and a modelled per-test cost of about $4.62 under planning assumptions declared in the accompanying script. The blueprint gives a full bill of materials at component-class level for each device (synthesis path, encapsulation and cartridge format, and reader instrument class for Device A; strand sets, reporter chemistry, sample-preparation and readout instrument class for Device B), manufacturing process steps in order, quality-control checkpoints with pass/fail numbers from the source designs, a costed build and operating estimate from the accompanying script, and operating limits and failure modes at full size. The CA19-9 aptamer transducer is printed at full size as an OPEN RISK: a load-bearing, unverified assumption — if no such aptamer performs as assumed, Device B as specified does not function. Nothing described has been built, synthesised in hardware, or clinically validated; no clinical use, diagnosis, sensitivity, or specificity is claimed.
No takes yet. Share an insight, caveat, or question.
William Alexander Aldred (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: